Loading…

CSL LimitedCSL.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Biotechnology

Global biotech making plasma-derived therapies, vaccines (Seqirus) and specialty medicines, with one of the largest plasma-collection networks worldwide.

≈ Australia's Grifols, but broader (plus a flu-vaccine arm)Momentum leader 98
Mkt cap
$63.7B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$126M
20-day average traded
Fwd P/E
21.5×
forward earnings
ROIC−WACC
+3.5 pp
WACC 7.1%
Hurdle
-4 pp
Req g minus delivered
Official | Implied
A- / A
agencies · bond market
Next earnings
83 days
9 Feb 2027
Close · AUDA$199.38
1D-0.1%
1W-1.1%
1M+1.6%
3M+18.5%
6M+102.5%
YTD+15.5%
1Y+11.8%
ATR %1.8%
52w lowhigh3.0% off high

What CSL does

Global biotech making plasma-derived therapies, vaccines (Seqirus) and specialty medicines, with one of the largest plasma-collection networks worldwide.

Earns most of its income from medicines made from human blood plasma, which it collects at its own donation centres, so access to plasma rather than demand is what limits growth. Seasonal flu vaccines through Seqirus are sold largely to governments and health systems. Most sales come from outside Australia, with the US the biggest market.

In one line: Australia's Grifols, but broader (plus a flu-vaccine arm).

Products and services

  • Plasma-derived therapies (immunoglobulins, albumin)
  • Influenza vaccines (Seqirus)
  • Specialty products (haemophilia, kidney disease)
  • Plasma collection centres

Customers

  • Hospitals and specialty pharmacies worldwide
  • Governments (vaccine procurement)
  • Patients with immune/bleeding disorders

Where it sits in the supply chain

  • Healthcare
  • Biopharmaceuticals
  • Plasma therapies + vaccines

What could go right

  • Plasma-collection volume recovery
  • Vaccine and specialty-drug launches

What could go wrong

  • Plasma-collection cost inflation
  • Biosimilar/generic competition

Moat: wide (scale, regulatory licence, IP / patents). Largest global plasma-collection network and regulatory approvals create a very high barrier to entry.

Headquarters: Melbourne, Australia · Founded: 1916 · Employees: 29,000

Named competitors

CSL at a glance

Size CSL (CSL.AX) is an Australia Health Care company (Biotechnology) with a market value of $63.7B, the 6th largest of 317 Australia companies the cockpit tracks. Shares closed at A$199.38 on 18 Nov 2026.

Performance Over six months the shares gained 102.5%, against +32.0% for the median peer and +1.2% for the Australia market (cap-weighted) — 3rd highest of 15 in its peer set.

Growth Revenue fell 2.5% over the last twelve months (peer median +11.0%); the operating margin is 25.7% (peer median 29.7%).

Valuation It trades at 21.5× forward earnings against a peer median of 26.5× (5th cheapest of 12).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.5 points above its cost of capital (7.1% WACC).

Credit CSL has 6 bonds outstanding ($4.00B), rated A- by the agencies and trading like A at a weighted spread of 98 bp.

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026CSL.AX 206Peer median 131
Six months, rebased to 100: CSL against the median of its 14 peers (local-currency closes).

CSL financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$23.2BA$23.2BA$23.8BA$22.4BA$19.6B
Revenue growth—-3%+6%+14%—
Gross profitA$11.1BA$11.1BA$11.6BA$10.9BA$9.46B
EBITDAA$7.49BA$7.46BA$7.79BA$7.08BA$5.60B
Net income-A$3.63B-A$3.81BA$4.64BA$4.03BA$3.34B
Free cash flowA$4.08BA$4.23BA$4.52BA$2.92BA$2.04B
Capital expenditureA$1.82BA$1.88BA$1.54BA$1.92BA$2.52B
Total debtn/aA$15.7BA$17.5BA$18.2BA$18.4B

Quarterly statements and history in the cockpit →

CSL competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%-20%0%+20%ARGXLONNMRNA207940IQVNTRA068270GMAB2269BNTXNBIXCSL.AX6-month return →1-month return →
Up and to the right = strong over both horizons. CSL is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×30×40×ARGXLONN207940IQV068270GMABUTHR2269GILDAMGNNBIXCSL.AXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CSL is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%ARGXLONN207940IQV068270UTHR2269CSL.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. CSL is the large dot.

CSL competitors and peer comparison

Head to head with its named competitors (CSL.AX vs GRF.MC vs 4502.T vs SAN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
CSL CSL.AX$63.7B+102%-2%26%21.5×6.8%
Grifols GRF.MC$7.48B+19%+1%16%13.1×7.1%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%

How CSL compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CSL against its 14 peers (data as of 18 Nov 2026)
MeasureCSL.AXPeer medianRank in peer set
1-month return+1.6%+2.7%8th highest of 15
6-month return+102.5%+32.0%3rd highest of 15
Distance from 52-week high-3.0%-12.4%2nd highest of 15
Revenue growth (TTM)-2.5%+11.0%4th lowest of 15
Operating margin25.7%29.7%7th lowest of 15
Forward P/E21.5×26.5×5th cheapest of 12
Growth the price implies (Req g, 7 yrs)6.8%10.6%5th least demanding of 12
Growth delivered (Del g)+11.0%+17.6%5th lowest of 12
Hurdle (Req g minus delivered)-4.2 pp-7.9 pp3rd most demanding of 12
ROIC minus cost of capital+3.5 pp+4.1 pp7th lowest of 15
EV / EBITDA14.8×16.7×cheapest of 12
Net debt / EBITDA1.8×1.2×4th most indebted of 12
Bond spread98 bp77 bp2nd widest of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CSL CSL.AXAustralia$63.7B+102%-2%26%21.5×6.8%+11.0%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%36.1×15.6%+7.7%
Moderna MRNAUnited States$79.6B+309%+13%-116%n/an/an/a
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%34.4×7.0%+31.4%
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Gilead Sciences GILDUnited States$210B+30%+7%38%19.9×-2.4%+3.6%
Amgen AMGNUnited States$240B+34%+9%36%18.3×1.6%+7.8%
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%

CSL bonds and credit

CSL has 6 bonds outstanding with $4.00B face value. The agencies rate it A-; its bonds trade like A. Weighted yield 6.04%, a spread of 98 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are CSL's main competitors?
Named competitors: Grifols (GRF.MC), Takeda Pharmaceutical (4502.T), Sanofi (plasma business) (SAN.PA), GSK (GSK.L). The cockpit's measured peer set (industry) also includes argenx SE Sponsored ADR (ARGX), Lonza (LONN.SW), Moderna (MRNA), Samsung Biologics (207940.KS), Iqvia (IQV), Natera (NTRA).
Is CSL expensive compared with its peers?
On forward p/e it trades at 21.5× against a peer median of 26.5×, 5th cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has CSL stock performed?
Over six months to 18 Nov 2026 the shares returned +102.5% against +32.0% for the median peer; over one year +11.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.